390 related articles for article (PubMed ID: 25200914)
1. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.
McDonnell MJ; Jary HR; Perry A; MacFarlane JG; Hester KL; Small T; Molyneux C; Perry JD; Walton KE; De Soyza A
Respir Med; 2015 Jun; 109(6):716-26. PubMed ID: 25200914
[TBL] [Abstract][Full Text] [Related]
2. A novel microbiota stratification system predicts future exacerbations in bronchiectasis.
Rogers GB; Zain NM; Bruce KD; Burr LD; Chen AC; Rivett DW; McGuckin MA; Serisier DJ
Ann Am Thorac Soc; 2014 May; 11(4):496-503. PubMed ID: 24592925
[TBL] [Abstract][Full Text] [Related]
3. Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients.
Dimakou K; Triantafillidou C; Toumbis M; Tsikritsaki K; Malagari K; Bakakos P
Respir Med; 2016 Jul; 116():1-7. PubMed ID: 27296814
[TBL] [Abstract][Full Text] [Related]
4. [Experience with nebulised colistin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa].
López-Gil Otero MM; Romero-Ventosa EY; Feijoo-Meléndez D; Casanova-Martínez C; Otero-Millán L; Piñeiro-Corrales G
Rev Esp Quimioter; 2019 Jun; 32(3):217-223. PubMed ID: 30924621
[TBL] [Abstract][Full Text] [Related]
5. Patients hospitalized with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics.
Venning V; Bartlett J; Jayaram L
Respirology; 2017 Jul; 22(5):922-927. PubMed ID: 28236369
[TBL] [Abstract][Full Text] [Related]
6. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
[TBL] [Abstract][Full Text] [Related]
7. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
8. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.
White L; Mirrani G; Grover M; Rollason J; Malin A; Suntharalingam J
Respir Med; 2012 Mar; 106(3):356-60. PubMed ID: 22204744
[TBL] [Abstract][Full Text] [Related]
10.
Taylor SL; Woodman RJ; Chen AC; Burr LD; Gordon DL; McGuckin MA; Wesselingh S; Rogers GB
Thorax; 2017 Apr; 72(4):304-310. PubMed ID: 27503233
[TBL] [Abstract][Full Text] [Related]
11. [Respiratory pathogen spectrum in pulmonary exacerbation of bronchiectasis in adults and its association with disease severity].
Gao YH; Guan WJ; Zhu YN; Chen RC; Zhang GJ
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Apr; 42(4):254-261. PubMed ID: 30955282
[No Abstract] [Full Text] [Related]
12. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis.
Davies G; Wells AU; Doffman S; Watanabe S; Wilson R
Eur Respir J; 2006 Nov; 28(5):974-9. PubMed ID: 16899482
[TBL] [Abstract][Full Text] [Related]
13. Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non-cystic fibrosis bronchiectasis patients.
Luo RG; Miao XY; Luo LL; Mao B; Yu FY; Xu JF
Clin Microbiol Infect; 2019 May; 25(5):601-606. PubMed ID: 30036669
[TBL] [Abstract][Full Text] [Related]
14. Microbiologic follow-up study in adult bronchiectasis.
King PT; Holdsworth SR; Freezer NJ; Villanueva E; Holmes PW
Respir Med; 2007 Aug; 101(8):1633-8. PubMed ID: 17467966
[TBL] [Abstract][Full Text] [Related]
15. Sputum bacteriology in steady-state bronchiectasis in Guangzhou, China.
Guan WJ; Gao YH; Xu G; Lin ZY; Tang Y; Li HM; Lin ZM; Zheng JP; Chen RC; Zhong NS
Int J Tuberc Lung Dis; 2015 May; 19(5):610-9. PubMed ID: 25868032
[TBL] [Abstract][Full Text] [Related]
16. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis.
Ho PL; Chan KN; Ip MS; Lam WK; Ho CS; Yuen KY; Tsang KW
Chest; 1998 Dec; 114(6):1594-8. PubMed ID: 9872194
[TBL] [Abstract][Full Text] [Related]
17. Eradication of
Blanco-Aparicio M; Saleta Canosa JL; Valiño López P; Martín Egaña MT; Vidal García I; Montero Martínez C
Chron Respir Dis; 2019; 16():1479973119872513. PubMed ID: 31480862
[TBL] [Abstract][Full Text] [Related]
18. Etiology and characteristics of patients with bronchiectasis in Taiwan: a cohort study from 2002 to 2016.
Huang HY; Chung FT; Lo CY; Lin HC; Huang YT; Yeh CH; Lin CW; Huang YC; Wang CH
BMC Pulm Med; 2020 Feb; 20(1):45. PubMed ID: 32070324
[TBL] [Abstract][Full Text] [Related]
19. Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis.
Alcaraz-Serrano V; Fernández-Barat L; Scioscia G; Llorens-Llacuna J; Gimeno-Santos E; Herrero-Cortina B; Vàzquez N; Puig de la Bellacasa J; Gabarrús A; Amaro-Rodriguez R; Menéndez R; Torres A
Respir Med; 2019; 154():40-46. PubMed ID: 31212120
[TBL] [Abstract][Full Text] [Related]
20. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.
Wilson CB; Jones PW; O'Leary CJ; Hansell DM; Cole PJ; Wilson R
Eur Respir J; 1997 Aug; 10(8):1754-60. PubMed ID: 9272915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
